A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis.

[1]  A. Anghel,et al.  Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics. , 2012, Acta histochemica.

[2]  D. Scherman,et al.  Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  M. Agulnik,et al.  Targeted therapies in bone sarcomas: current approach and future directions , 2011, Expert opinion on investigational drugs.

[4]  Maeve Mullooly,et al.  The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? , 2011, Clinical Proteomics.

[5]  D. Heymann,et al.  Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.

[6]  G. Moriceau,et al.  Therapeutic approach of primary bone tumours by bisphosphonates. , 2010, Current pharmaceutical design.

[7]  M. Sonobe,et al.  A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma , 2009, Journal of surgical oncology.

[8]  D. Edwards,et al.  The ADAM metalloproteinases , 2008, Molecular Aspects of Medicine.

[9]  S. Raza,et al.  Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment , 2008, Cancer Epidemiology Biomarkers & Prevention.

[10]  Y. Okada,et al.  ADAMs in cancer cell proliferation and progression , 2007, Cancer science.

[11]  T. Ørntoft,et al.  Molecular Profiling of ADAM12 in Human Bladder Cancer , 2006, Clinical Cancer Research.

[12]  M. Bonneville,et al.  Complex Interplay of Activating and Inhibitory Signals Received by Vγ9Vδ2 T Cells Revealed by Target Cell β2-Microglobulin Knockdown1 , 2006, The Journal of Immunology.

[13]  D. Heymann,et al.  Osteosarcoma: current status of immunotherapy and future trends (Review). , 2006, Oncology reports.

[14]  J. Foidart,et al.  Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC) , 2006, British Journal of Cancer.

[15]  M. Harting,et al.  Management of osteosarcoma pulmonary metastases. , 2006, Seminars in pediatric surgery.

[16]  P. Kronqvist,et al.  A role for ADAM12 in breast tumor progression and stromal cell apoptosis. , 2005, Cancer research.

[17]  E. Kleinerman,et al.  Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. , 2005, Cancer research.

[18]  D. Zurakowski,et al.  ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage* , 2004, Journal of Biological Chemistry.

[19]  T. Shiomi,et al.  Tumorigenesis and Neoplastic Progression ADAM12 Is Selectively Overexpressed in Human Glioblastomas and Is Associated with Glioblastoma Cell Proliferation and Shedding of Heparin-Binding Epidermal Growth Factor , 2004 .

[20]  K. Mark,et al.  Interaction of the disintegrin and cysteine-rich domains of ADAM12 with integrin α7β1 , 2004 .

[21]  S. Ferrari,et al.  Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Tomoyuki Saito,et al.  Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. , 2002, Cancer letters.

[23]  L. Shultz,et al.  Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. , 2002, In vivo.

[24]  H. Chien,et al.  Down-Regulation of Osteoblastic Cell Differentiation by Epidermal Growth Factor Receptor , 2000, Calcified Tissue International.

[25]  R. Fässler,et al.  The Cysteine-Rich Domain of Human Adam 12 Supports Cell Adhesion through Syndecans and Triggers Signaling Events That Lead to β1 Integrin–Dependent Cell Spreading , 2000, The Journal of cell biology.

[26]  A. Zallone,et al.  Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. , 2000, Biochemical and biophysical research communications.

[27]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[28]  Jan-Kan Chen,et al.  Differential inhibitory effects of TGF‐β on EGF‐, PDGF‐, and HBGF‐1‐stimulated MG63 human osteosarcoma cell growth: Possible involvement of growth factor interactions at the receptor and postreceptor levels , 1989, Journal of cellular physiology.

[29]  E. Canalis,et al.  Direct stimulation of bone resorption by epidermal growth factor. , 1980, Endocrinology.

[30]  J. Couchman,et al.  Cellular roles of ADAM12 in health and disease. , 2008, The international journal of biochemistry & cell biology.

[31]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[32]  Hiroshi Asanuma,et al.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.

[33]  J. Chirgwin,et al.  Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.